NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.
Follow NVCR
NovoCure Limited (NVCR) EV/Sales
As of 16 October 2026, NovoCure Limited (NVCR) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.6× (December 2025) to 43.3× (June 2021); the current reading is higher than 12% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | (54.04%) |
| FY2024 | 3.9× | 67.72% |
| FY2023 | 2.3× | (81.29%) |
| FY2022 | 12.5× | (9.72%) |
| FY2021 | 13.8× | (59.93%) |
| FY2020 | 34.5× | 51.08% |
| FY2019 | 22.8× | 90.20% |
| FY2018 | 12.0× | 24.22% |
| FY2017 | 9.7× | 46.07% |
| FY2016 | 6.6× | (49.53%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.1× | 39.75% |
| Mar 2026 | 1.5× | (14.49%) |
| Dec 2025 | 1.8× | 91.14% |
| Sep 2025 | 0.9× | (49.29%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNMD CONMED Corporation compare | 1.6× |
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| BVS Bioventus Inc. compare | 1.9× |
| NVCR NovoCure Limited | 2.0× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)